Mouse NEFL ELISA Kit
- Known as:
- Mouse NEFL Enzyme-linked immunosorbent assay test Kit
- Catalog number:
- abx154439
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Abbexa
- Gene target:
- Mouse NEFL ELISA Kit
Related genes to: Mouse NEFL ELISA Kit
- Gene:
- NEFL NIH gene
- Name:
- neurofilament light
- Previous symbol:
- -
- Synonyms:
- NFL, CMT1F, CMT2E, NF68, PPP1R110
- Chromosome:
- 8p21.2
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: Mouse NEFL ELISA Kit
Related articles to: Mouse NEFL ELISA Kit
- Although cerebrospinal fluid (CSF) biomarkers reflect neurodegeneration in Alzheimer's disease (AD), it remains unclear whether these biomarkers track neurodegeneration in early-onset Alzheimer's disease (EOAD). - Source: PubMed
Touroutoglou AlexandraKatsumi YutaHensel JenniferSchindler Suzanne EIbanez LauraBrickhouse MichaelEloyan AniEckbo RyanZaitsev AlexanderLa Joie RenaudThangarajah MaryanneTaurone AlexanderVemuri PrashanthiJack Clifford RHammers Dustin BForoud TatianaAisen PaulBeckett LaurelKoeppe RobertKukull Walter AToga ArthurAtri AlirezaClark DavidDay Gregory SDuara RanjanGraff-Radford Neill RGrant Ian MHonig Lawrence SJohnson Erik C BJones David TMasdeu Joseph CMendez Mario FMusiek ErikOnyike Chiadi URiddle MeghanRogalski EmilySalloway StephenSha SharonTurner R ScottWingo Thomas SWolk David AWomack KyleCarrillo Maria CRabinovici Gil DApostolova Liana GDage Jeffrey LDickerson Bradford CEldaief Mark C - Neurofilament light chain (NfL) is a structural axonal protein measurable in CSF and blood, increasingly investigated as a biomarker of neuroaxonal injury in clinical and research contexts. This review aims to explore the use of blood-based NfL as an endpoint in clinical trials of neurodegenerative conditions. - Source: PubMed
Publication date: 2026/07/20
Zheng YumingBhalala Oneil GChin Kai SinWatson RosieYassi Nawaf - Plasma phosphorylated tau (p-tau) biomarkers have improved the diagnosis of Alzheimer's disease (AD), but evidence in early-onset populations remains limited. We evaluated the diagnostic performance of plasma p-tau217 and p-tau181 levels in patients with early-onset AD (EOAD) and early-onset frontotemporal dementia (EOFTD). - Source: PubMed
Publication date: 2026/07/20
Kwon Hyuk SungMoon So YoungHwang MinaKim Hee JinLee Sun MinJung Na-YeonJang HyeminBaek Jeong-MinKim Min-JuHan Myung-HoonZetterberg HenrikBlennow KajApostolova Liana GKoh Seong-HoKim Eun-Joo - The GM2 gangliosidoses (GM2) are ultra-rare neurodegenerative disorders caused by deficient hexosaminidase A and/or B activity, leading to lysosomal GM2 ganglioside accumulation. Disease onset ranges from infancy to adulthood, with earlier onset associated with more rapid progression. Neurofilament light chain (NfL), a sensitive marker of axonal injury, has been extensively investigated as a biomarker for neurodegenerative disorders, including GM2. - Source: PubMed
Publication date: 2026/07/17
Martakis KyriakosAbreu Nicolas JBaker Joshua JBaker Ii Peter RBillington IanBurrow T AndrewFactor MalloryFields TaylorFields CassandraGannon Jennifer LGrosso MeganKerthi JorgjiPatterson Marc CShayota Brian JStrupp MichaelStrupp LennardBremova-Ert Tatiana - Using multi-shell diffusion MRI, we aimed to identify whether corticospinal tract (CST) subfiber damage can be detected in prediagnostic amyotrophic lateral sclerosis (ALS) patients. We also explored whether the combination of serum neurofilament light chain (NfL) levels and CST subfiber abnormalities may provide better diagnostic performance in differentiating prediagnostic ALS patients from disease controls (DCs) and healthy controls (HCs) than single markers. - Source: PubMed
Gao NingluCui BoYun YanYu WenfeiGao XianleiSun XiaohanShao KaiLin PengfeiLiu FuchenLi WeiZhao YuyingYu DexinYan ChuanzhuLiu ShuangwuLou Jianwei